01.04.2016
STRATEC Biomedical AG DE000STRA555
DGAP-News: STRATEC completes acquisition of Diatron
DGAP-News: STRATEC Biomedical AG / Key word(s): Takeover/Acquisition
STRATEC completes acquisition of Diatron
01.04.2016 / 16:53
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
STRATEC completes acquisition of Diatron
Birkenfeld, April 1, 2016
STRATEC Biomedical AG, Birkenfeld, Deutschland (Frankfurt: SBS; Prime
Standard, TecDAX) today announces the successful completion of the
acquisition of Diatron MI PLC (Diatron). On March 23, 2016, STRATEC
announced that it entered into an agreement with the global private equity
firm The Riverside Company governing the full acquisition of Diatron, its
US affiliate company and the superordinate holding structure.
With the acquisition of Diatron, STRATEC is extending its range of products
and its customer base in the hematology segment. Diatron's OEM portfolio
chiefly comprises analyzer systems, system components, consumables and
tests in the lower throughput segment for hematology applications.
About STRATEC
STRATEC Biomedical AG (www.stratec.com) designs and manufactures fully
automated analyzer systems for its partners in the fields of clinical
diagnostics and biotechnology. These partners market such systems, in
general together with their own reagents, as system solutions to
laboratories, blood banks and research institutes around the world. The
company develops its products on the basis of its own patented
technologies.
Shares in the company (ISIN: DE000STRA555) are traded in the Prime Standard
segment of the Frankfurt Stock Exchange and are listed in the TecDAX select
index of the German Stock Exchange.
Further information can be obtained from:
STRATEC Biomedical AG
André Loy, Corporate Communications
Gewerbestr. 37, 75217 Birkenfeld
Germany
Tel: +49 7082 7916-190
Fax: +49 7082 7916-999
[email protected]
www.stratec.com
---------------------------------------------------------------------------
01.04.2016 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: STRATEC Biomedical AG
Gewerbestr. 37
75217 Birkenfeld
Germany
Phone: +49 (0)7082 7916 0
Fax: +49 (0)7082 7916 999
E-mail: [email protected]
Internet: www.stratec.com
ISIN: DE000STRA555
WKN: STRA55
Indices: TecDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover,
Munich, Stuttgart, Tradegate Exchange; Terminbörse EUREX
End of News DGAP News Service
---------------------------------------------------------------------------
450747 01.04.2016
|
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu
STRATEC Biomedical AG ISIN: DE000STRA555 können Sie bei EQS abrufen
Medtech , STRA55 , SBS , XETR:SBS